Natural Health Care with Results
Cyrex Functional Immunology and Autoimmunity Assessments
Cyrex Labs is a Clinical Immunology Laboratory Specializing in Functional Immunology and Autoimmunity. They offer multi-tissue antibody testing for the early detection and monitoring of today’s complex autoimmune conditions. Their tests address the cross-connections between the body’s endocrine, gastrointestinal and neurological systems which play a significant role in the development of today’s complex disorders.
Presently, Cyrex Labs offers 18 different arrays or panels to assess immunological and autoimmunity activity.
To view the sample reports, see the links below.
This unique, revolutionary panel measures reactivity to 180 food antigens in the cooked, raw, modified or processed form on the same panel. Assists in early detection of dietary-related triggers of autoimmune reactivity and monitors the effectiveness of customized dietary protocols.
This test gives you the same unique, revolutionary features you get from the Array 10 - Multiple Food Immune Reactivity Screen test and includes an additional 90 food antigens from the Array 10 test. The Array 10-90X also features all Cyrex’s proprietary food testing technologies.
The test assists in the early detection of dietary-related triggers of autoimmune reactivity and monitors the effectiveness of customized dietary protocols.
This test gives you the same unique, revolutionary features you get from the Array 10 - Multiple Food Immune Reactivity Screen test and measures reactivity to 90 food antigens most commonly consumed, whereas the Array 10 test measures reactivity to 180 food antigens. The Array 10-90 also features all Cyrex’s proprietary food testing technologies.
The test assists in the early detection of dietary-related triggers of autoimmune reactivity and monitors the effectiveness of customized dietary protocols.
Toxic heavy metals and chemicals are all around us, in our environment and in our foods. The Array 11 text identifies body burden of chemicals bound to human tissues, which may lead to autoimmune reactivity.
We are continuously and consistently deluged with environmental toxins. Starting with increasing chemical production in the United States right after World War II, we manufacture 5 trillion pounds of 70,000 different chemicals per year, of which only 1,500 have been studied for toxicity.
The Array 12 test detects immune reaction to key pathogens that may lead to multiple autoimmune reactivities. This test determines the role of pathogens in cases of 'unexplained' autoimmune reactivities and monitors the effectiveness of clinical protocols for addressing pathogens associated with multiple autoimmunities.
This test is indicated for:
-
Those who present with chronic conditions such as gastrointestinal distress, fatigue, body aches or unexplained and general inflammation, including neuroinflammation.
-
Those who may have been exposed to bacteria, viruses, parasites, molds, and spirochetes associated with multiple autoimmunities.
-
Those who test negative for dietary proteins and tissue-bound chemical antibodies, yet continue to present symptoms associated with autoimmunities.
-
Those who have not fully responded to clinical interventions, such as detoxification and dietary modifications.
Home to 70% of the immune system, the mucosal immune system acts as the primary host defense against the physical environmental factors (food, airborne molecules, viruses and commensal antigens), and plays a significant role in barrier functions. Mucosal immunity is the main functional defense mechanism in the urinary, respiratory, and the gastrointestinal systems.
This Array is a very cost effective, easy, and non-invasive method, to measure mucosal immune reactivity to a range of exogenous [growing or originating from outside an organism] and endogenous [growing or originating from within an organism] antigens. The categories of antigens include assessments for intestinal dysfunction, food immune reactivity, gut dysbiosis, infection, and possible enteric nervous system autoimmune reactivity. This mucosal immune response is the body’s first immune system reaction. If steps to bring balance back to the mucosal immune response are not taken, the immune reactivity may result in a breach of the intestinal barrier, followed by a systemic immune reaction. The inflammation of systemic autoantibodies contributes to the progression of autoimmune and neuroautoimmune reactivities.
The Array 2 test measures intestinal permeability to large molecules, which inflame the immune system. It identifies the route of damage to the intestinal barrier and the presence of immune reactivity to Lipopolysaccharides (LPS), a key indicator of systemic inflammation leading to autoimmune conditions.
The Antibody Array Panel 2 - Intestinal Antigenic Permeability Screen is an extremely sensitive marker of the dysfunctional epithelial barrier, allowing macromolecular penetration from the lumen of the intestines into systemic circulation.
Measurement of intestinal barrier permeability is recommended for:
-
Those who present multiple symptom complaints (including Chronic Fatigue Syndrome)
-
Those who suffer from abnormal immune cell count and function (including autoimmune diseases)
-
Those who have gut dysbiosis, which appears to be resistant to standard therapy
-
Those who are suspected of having intestinal mucosal damage
-
Those who have or complain of multiple food sensitivities, food allergies or food intolerance
-
Those who are suspected of suffering from blood-brain barrier permeability, depression, or neuroautoimmunity
The Array 20 Blood Brain Barrier Permeability test assists in the assessment of increased risk of neurodegenerative disorders, including but not limited to multiple sclerosis, Lou Gehrig's disease, senile dementia, Alzheimer's Disease, Parkinson's disease, epilepsy and stroke. It helps in the early investigation of contact sports-related Traumatic Brain Injury, and evaluates the breach of the blood-brain barrier caused by stress, trauma or environmental triggers, even in the absence of apparent concussion or brain injury.
The blood brain barrier (BBB) is a physical barrier between the brain and the circulating blood, formed by the arrangement of endothelial cells and tight junctions that line the capillaries, which supply blood to the brain.
The Array 22 - Irritable Bowel/SIBO Screen test identifies the release of bacterial cytotoxins by the large intestinal bacteria that cause irritable bowels and/or SIBO and evaluates a breakdown of the intestinal barrier.
Cyrex’s Array 22 – Irritable Bowel / SIBO Screen test assesses IgG, IgA and IgM antibodies to Bacterial Cytotoxins and to Cytoskeletal Proteins. Cytotoxins are lethal xenobiotics released by commensal coliform bacteria.
Coliform bacteria are rod-shaped bacteria, especially Escherichia coli and members of the genus Aerobacter, found in the intestinal tract of humans and other animals. Its presence in water indicates fecal contamination and can cause diarrhea and other dysenteric symptoms.
The Array 3x Wheat/Gluten Proteome Reactivity & Autoimmunity Array test assists in the identification of wheat reactivity, non-celiac gluten sensitivity, Celiac disease, food opioid reactivity, intestinal barrier damage and wheat-related autoimmunity.
Gluten-Reactivity has been proposed to include not only Celiac disease, but also non-celiac gluten sensitive (NCGS) in patients without mucosal lesions. From the skin (dermatitis herpetiformis, psoriatic arthritis, alopecia areota, dermatomyositis, cutaneous vasculitis, to the muscles (inflammatory myopathies), to the brain (gluten ataxia, altered neurotransmitter production, schizophrenia, peripheral neuralgias, idiopathic neuropathies) and beyond, pathology to gluten exposure can occur in multiple systems without evidence of an enteropathy.
The Array 4 test identifies reactivity to foods known to cross-react to gliadin and reactivity to newly introduced foods on a gluten-free diet.
Once a patient is diagnosed as Celiac disease (CD) or having Gluten Reactivity, he/she is instructed to adhere to a gluten-free diet. Brochures, books and websites help the patient with this seemingly difficult process. However, a significant percentage of these patients will continue to have gluten-like complaints even after being on a gluten-free diet (GFD) for months.
The Array 4 test can assist the clinician by detecting both sensitivities and cross-reactions and thus reveal the possible cause of this continued gluten-like reaction in the patient.
The Array 5 test measures predictive autoantibodies, some of which can appear up to 10 years before clinical symptoms. It also efficiently and economically assesses possible tissue damage to multiple organs of the body.
Clinical autoimmune disease is preceded by complicated autoimmune changes that are usually under way for many years before diagnosis. In autoimmune diseases, the immune system manufactures antibodies that target the body’s own tissues. When an autoimmune condition (such as a gluten sensitive enteropathy) is diagnosed early, it is possible that gluten has not caused serious damage yet and only findings may include mild histological damage associated with subclinical or silent disease. Thus, identifying the presence of these antibodies becomes an early-warning system as to what tissue damage may be developing for the patient allowing the development of an intervention protocol, which may reverse the development of the autoimmune disease.
The Cyrex Array 6 Diabetes Autoimmune Reactivity screen test evaluates antibodies against Glutamic Acid Decarboxylase 65 (GAD65), insulin and the islet cells.
Islet cells are found in the region of the pancreas that contains its hormone-producing cells. This test can be used to help identify the onset of autoimmune diabetes. It may also be useful in monitoring a current diagnosis of Type 1 diabetes and the effectiveness of treatment.
The Neurological Autoimmune Reactivity Screen Array 7 and Array 7 expanded tests are useful tools to help assist in the early detection of neuro-autoimmunity. These tests can highlight the severity of the autoimmune response, and assist in monitoring the effectiveness of current wellness plans.
There are two versions of the Array 7. The Array 7 looks at IgG and IgA responses where as the Array 7x Expanded also assesses IgM.
The Neurological Autoimmune Reactivity Screen Array 7 and Array 7 expanded tests are useful tools to help assist in the early detection of neuro-autoimmunity. These tests can highlight the severity of the autoimmune response, and assist in monitoring the effectiveness of current wellness plans.
There are two versions of the Array 7. The Array 7 looks at IgG and IgA responses where as the Array 7x Expanded also assesses IgM.
By including IgM, the Cyrex Array 7X Neurological Autoimmune Reactivity Screen Expanded test helps with early detection of neuro-autoimmune reactivity, the identification of multi-focal motor neuropathy, lower motor neuron syndromes, earlier development of relapses in multiple sclerosis and chronic inflammatory demyelinating polyneuropathy, and as a tool to monitor the effectiveness of related treatment protocols.
The Cyrex Array 8 Joint Autoimmune Reactivity Screen test assists in the detection of connective tissue disorders - for those who have arthritis, arthralgias or joint inflammation following exposure to environmental triggers. It also monitors the effectiveness of related treatment protocols.
The Alzheimer's LINX test makes it easier to identify the route of pathogenesis leading to cognitive decline and devise strategies to stop it. By addressing the blood-brain barrier breakdown, identifying and removing triggers and enhancing neuronal regeneration, one might be able to win the war on cognitive decline.
The test panel assesses seven key groups of antibodies produced by the immune system against internal factors as well as certain environmental triggers (pathogens, foods, and toxic chemicals) that are linked to the potential development of Alzheimer's disease.
The Lymphocyte MAP is an innovative test which establishes a new standard in screening the immune system. It measures the integrity of the immune system at the cellular level to help identify a patient's immune status and immunotype(s), based on 28 key biomarkers and determinants.
The Lymphocyte MAP identifies the patterns of balance or imbalance of T cells B-cells and natural killer cells detected in the blood of a patient, and organizes them into specific immunotypes to facilitate interpretation of test results.